
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4141945</article-id><article-id pub-id-type="pmid">25128002</article-id><article-id pub-id-type="publisher-id">1877</article-id><article-id pub-id-type="doi">10.1186/1472-6882-14-301</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Effect of electroacupuncture versus pelvic floor muscle training plus solifenacin for moderate and severe mixed urinary incontinence in women: a study protocol </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Baoyan</given-names></name><address><email>gamlby@163.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yang</given-names></name><address><email>migofree@126.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Huanfang</given-names></name><address><email>huanfang_xu@126.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yuelai</given-names></name><address><email>chenyuelai@163.com</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jiani</given-names></name><address><email>handsom_mars@126.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Mo</surname><given-names>Qian</given-names></name><address><email>duoduo425@126.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Zhishun</given-names></name><address><email>liuzhishun@aliyun.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><aff id="Aff5"><label/>Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No.5 Beixiange Street, Beijing, Xicheng District China </aff><aff id="Aff6"><label/>Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, Pudong China </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>301</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>© Liu et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>In women with mixed urinary incontinence, pelvic floor muscle training and solifenacin is the recommended conservative treatment, while electroacupuncture is a safe, economical and effective option. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="3" pm="."><plain>Methods/Design </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>In this prospective, multi-center, randomized controlled trial, five hundred women with mixed urinary incontinence, from 10 centers will be randomized to receive either electroacupuncture or pelvic floor muscle training plus solifenacin. </plain></SENT>
<SENT sid="5" pm="."><plain>Women in the acupuncture group will receive electroacupuncture for 3 sessions per week, over 12 weeks, while women in the control group will receive pelvic floor muscle training plus solifenacin (5 mg once daily) for 36 weeks. </plain></SENT>
<SENT sid="6" pm="."><plain>The primary outcome measure is the proportion of change in 72-hour incontinence episode frequency from baseline to week 12. </plain></SENT>
<SENT sid="7" pm="."><plain>The secondary outcome measures include eleven items, including proportion of participants with ≥50% decrease in average 72-h incontinence episode frequency, change from baseline in the amount of urine leakage and proportion of change from baseline in 72-h incontinence episode frequency in week 25–36, and so forth. </plain></SENT>
<SENT sid="8" pm="."><plain>Statistical analysis will include covariance analysis, nonparametric tests and t tests. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="9" pm="."><plain>Discussion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>The objective of this trial is to compare the efficacy and safety of electroacupuncture versus pelvic floor muscle training plus solifenacin in women with moderate and severe mixed urinary incontinence. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>Trial registration </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://register.clinicaltrials.gov/">NCT02047032</ext-link> </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Electroacupuncture</kwd><kwd>Pelvic floor muscle training</kwd><kwd>Solifenacin</kwd><kwd>Mixed urinary incontinence</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1"><title><text><SENT sid="13" pm="."><plain>Background </plain></SENT>
</text></title><p><text><SENT sid="14" pm="."><plain>The International Urogynecological Association/International Continence Society defines mixed urinary incontinence (MUI) as “the complaint of involuntary loss of urine associated with urgency and also with effort or physical exertion or on sneezing or coughing” [1]. </plain></SENT>
<SENT sid="15" pm="."><plain>MUI occurs when symptoms of both stress urinary incontinence (SUI) and urgency urinary incontinence (UUI) are present. </plain></SENT>
<SENT sid="16" pm="."><plain>According to the literature, the prevalence of MUI in women range from 16 to 61% [1–3]. </plain></SENT>
<SENT sid="17" pm="."><plain>In China, the prevalence is 9.4% [4]. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>The treatment of MUI is challenging because the symptoms of SUI and UUI occur concurrently. </plain></SENT>
<SENT sid="19" pm="."><plain>Management options include absorbent products, behavioral modification, medical management, and surgery. </plain></SENT>
<SENT sid="20" pm="."><plain>Behavioral therapy (such as lifestyle modification, bladder training and pelvic floor muscle training (PFMT)) should be considered as a first-line option for all women with MUI [5, 6]. </plain></SENT>
<SENT sid="21" pm="."><plain>Although recommended for MUI, PFMT is the most commonly recommended physical therapy for women with SUI [7]. </plain></SENT>
<SENT sid="22" pm="."><plain>Its benefit seems to be greater in women with SUI alone as compared with women with mixed SUI and UUI [8]. </plain></SENT>
<SENT sid="23" pm="."><plain>Thus, for the treatment of MUI, drug therapy is usually used in combination with PFMT [9]. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>Solifenacin is a M3 receptor selective antimuscarinic agent, launched in 2005 for the treatment of overactive bladder. </plain></SENT>
<SENT sid="25" pm="."><plain>It relieves the symptoms of frequency, urgency, nocturia and urgency incontinence [10]. </plain></SENT>
<SENT sid="26" pm="."><plain>In a meta-analysis of seven studies, the mean and median reduction in the number of urgency episodes with solifenacin was greater than with several other agents such as oxybutynin, tolterodine, trospium, and darifenacin [11]. </plain></SENT>
<SENT sid="27" pm="."><plain>For this study, the combination of PFMT and solifenacin will serve as a control against electroacupuncture. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Acupuncture has a long history and is a widely used conservative treatment option for many diseases, including urinary incontinence. </plain></SENT>
<SENT sid="29" pm="."><plain>A literature review showed that acupuncture improves symptoms of both SUI and UUI, and it seems to have long-term benefits [12–14]. </plain></SENT>
<SENT sid="30" pm="."><plain>Based on this, acupuncture is a reasonable treatment option for MUI. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>This is a protocol for a prospective, multi-center, randomized controlled trial. </plain></SENT>
<SENT sid="32" pm="."><plain>The primary objective of the study is to compare the effect of electroacupuncture (EA) versus PFMT plus solifenacin in patients with MUI. </plain></SENT>
<SENT sid="33" pm="."><plain>The secondary objective is to ascertain whether EA is effective for another 12 to 24 weeks after the therapy. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2"><title><text><SENT sid="34" pm="."><plain>Methods and design </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="35" pm="."><plain>Study design </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>This study is a prospective, randomized controlled trial and will be conducted from March 2014 to August 2015 across 10 hospitals in Chinaa. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>Participants with urinary incontinence will be recruited through advertisements in newspapers, on television, on websites and posters. </plain></SENT>
<SENT sid="38" pm="."><plain>The diagnosis of incontinence type and severity will be made by a gynecologist or a urologist [15]. </plain></SENT>
<SENT sid="39" pm="."><plain>After obtaining informed consent, patients with moderate MUI will receive a 1-week baseline assessment, including a 72-hour voiding diary, a 1-hour pad test, routine urinalysis, a urine flow rate assessment and a bladder ultrasound. </plain></SENT>
<SENT sid="40" pm="."><plain>Randomization will be performed centrally by the Clinical Evaluation Center of the China Academy of Chinese Medical Sciences in Beijing, and eligible participants will be randomized to the EA group or the control group. </plain></SENT>
<SENT sid="41" pm="."><plain>A randomization number will be sent immediately to the acupuncturist by phone or online. </plain></SENT>
<SENT sid="42" pm="."><plain>The statisticians, outcome assessors, the gynecologists and urologists will be blinded to the allocation. </plain></SENT>
<SENT sid="43" pm="."><plain>The flowchart of the trial is presented in Figure 1. </plain></SENT>
<SENT sid="44" pm="."><plain>The trial protocol is in accordance with the principles of the Declaration of Helsinki and has been approved by the review board and ethics committee of the participating hospitals (Ethics approval number: 2013EC125-01).Figure 1 The flowchart.  </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="45" pm="."><plain>Participants </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>Five hundred participants will be needed in this trial. </plain></SENT>
<SENT sid="47" pm="."><plain>Patients meeting the diagnostic criteria of concomitant SUI and UUI will be diagnosed as mixed urinary incontinence. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Diagnostic criteria of SUI: 1) involuntary loss of urine on effort or physical exertion, or on sneezing or coughing; 2) positive in urinary stress test. </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>Diagnostic criteria of UUI: unwanted urine loss that happens shortly after the sudden, intense desire to urinate. </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="50" pm="."><plain>Inclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="51" pm="."><plain>Participants who meet the following criteria will be included: 1) confirmation of mixed urinary incontinence; 2) aged 35–75 years; 3) moderate and severe urinary incontinence with a urinary incontinence severity index between 3 and 9 [16] 4) a history of urinary incontinence for at least 3 months and a 72-hour incontinence episode frequency (IEF) ≥2 at baseline; 5) volunteer to join this research and give informed consent prior to receiving treatment. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="52" pm="."><plain>Exclusion criteria </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>Participants with any of the following conditions will be excluded: 1) stress urinary incontinence, urgency urinary incontinence, overflow incontinence or neurogenic bladder; 2) the use of medication for urinary incontinence, medication that may affect bladder function, or the use of any non-drug therapy (such as electric stimulation, bladder training and pelvic floor muscle training) in the prior month; 3) symptomatic urinary tract infection and non-functional urologic disease; 4) history of surgery for urinary incontinence or to the pelvic floor (including hysterectomy); 5) second-degree or greater pelvic organ prolapse; 6) residual urinary volume (RUV) &gt;30 mL; 7) maximum flow rate (Qmax) &lt;20 mL/s; 8) allergy to solifenacin or contraindications to muscarinic antagonists (such as urinary retention, gastric retention, myasthenia gravis, ulcerative colitis and angle closure glaucoma); 9) diseases affecting the functioning of the lower urinary tract (such as uncontrolled diabetes, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, spinal injury, cauda equina injury and multiple system atrophy); 10) serious cardiovascular, pulmonary, cerebral, liver, kidney, blood or psychiatric disease and cognitive impairment; 11) severe renal dysfunction or moderate hepatic dysfunction with concomitant strong CYP3A4 inhibitor use (such as ketoconazole); 12) limited or no ability to walk up and down stairs and running; 13) poor compliance with EA, pelvic floor muscle training or medication; 14) pregnancy, lactation or within 12 months postpartum; 15) a cardiac pacemaker, a metal allergy, or a severe needle phobia; 16) volunteer in other trials. </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="54" pm="."><plain>Intervention </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>All participants will be advised of lifestyle modification, including: 1) weight management (participants with a BMI ≥30 would be advised to lose weight); 2) fluid intake (1.5 to 2 L in 24 hours) 3); caffeine reduction. </plain></SENT>
<SENT sid="56" pm="."><plain>Therapies other than the treatment regimen are prohibited during the trial. </plain></SENT>
</text></p><sec id="Sec8"><title><text><SENT sid="57" pm="."><plain>Treatment group </plain></SENT>
</text></title><p><text><SENT sid="58" pm="."><plain>BL33 point and BL35 point of both sides are used. </plain></SENT>
<SENT sid="59" pm="."><plain>For BL33, the needle will be inserted at the third sacral foramen at an angle of 30–45° and to a depth of 50–60 mm. </plain></SENT>
<SENT sid="60" pm="."><plain>The needle will be manipulated with an even lifting, thrusting and twisting method and a sense of soreness and distention will radiate to the perineum or the anus. </plain></SENT>
<SENT sid="61" pm="."><plain>For BL35, the needle will be inserted upward and outward and then manipulated with an even lifting, thrusting and twisting method and a sense of soreness and distention will radiate to the perineum or the anus. </plain></SENT>
<SENT sid="62" pm="."><plain>An electric stimulator will be placed on the pair of points with a spare-dense wave, 10/50 Hz, 0.1–5.0 mA. </plain></SENT>
<SENT sid="63" pm="."><plain>The current intensity will be increased to maximum tolerance and then reduced to a bearable limit. </plain></SENT>
<SENT sid="64" pm="."><plain>Following a review of the Chinese literature published in the last 10 years, together with the results of a phase I trial and expert consensus, all patients will receive 36 acupuncture sessions (3 sessions per week for 12 weeks), with each session lasting 30 minutes and administered every other day. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="65" pm="."><plain>Control group </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>The control group will receive PFMT plus solifenacin for a period of 36 weeks. </plain></SENT>
<SENT sid="67" pm="."><plain>Solifenacin (Astellas Pharma Europe B.V.) will be taken at a dose of 5 mg once daily, before or after a meal. </plain></SENT>
<SENT sid="68" pm="."><plain>PFMT will include intensive exercises conducted in hospital and home exercises. </plain></SENT>
<SENT sid="69" pm="."><plain>Intensive exercises will be done once a week for the first 12 weeks and once every four weeks for weeks 13–36. </plain></SENT>
<SENT sid="70" pm="."><plain>Home exercises will be done three times daily for 36 weeks. </plain></SENT>
<SENT sid="71" pm="."><plain>The intensity of the exercises will conform to the National Institute for Health and Clinical Excellence (NICE) [17] guidelines. </plain></SENT>
</text></p></sec></sec><sec id="Sec10"><title><text><SENT sid="72" pm="."><plain>Outcome measures </plain></SENT>
</text></title><p><text><SENT sid="73" pm="."><plain>In this study, there is one primary outcome and eleven secondary outcomes. </plain></SENT>
<SENT sid="74" pm="."><plain>These are presented in Table 1. </plain></SENT>
<SENT sid="75" pm="."><plain>Safety evaluation for EA will be based on events which include fainting, severe pain, hematoma, local infection, and any feelings of discomfort. </plain></SENT>
<SENT sid="76" pm="."><plain>Any adverse event resulting from EA or adverse drug reaction to solifenacin will be recorded.Table 1 Outcome measures  </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="77" pm="."><plain>Data collection and quality control </plain></SENT>
</text></title><p><text><SENT sid="78" pm="."><plain>Two researchers will input data independently using the Remote Data Capture (RDC) software. </plain></SENT>
<SENT sid="79" pm="."><plain>A Data Verification Plan (DVP) will be established to review the data after input. </plain></SENT>
<SENT sid="80" pm="."><plain>Two data managers with a medical background will perform coding for the medical history, adverse events and drug combinations. </plain></SENT>
<SENT sid="81" pm="."><plain>After a data review, the data will be submitted to the statistician for final analysis. </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>To guarantee the quality of the trial, a rigorous methodology will be followed. </plain></SENT>
<SENT sid="83" pm="."><plain>Before commencing the trial, experts in different fields will be invited to review and revise the protocol, and staff from the 10 trial centers will undergo training. </plain></SENT>
<SENT sid="84" pm="."><plain>A 3-level monitoring system will be established to check the performance of the trial periodically. </plain></SENT>
<SENT sid="85" pm="."><plain>Outcome assessments, completion of case report forms and data management will be closely supervised. </plain></SENT>
</text></p></sec><sec id="Sec12"><title><text><SENT sid="86" pm="."><plain>Sample size and statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="87" pm="."><plain>Sample size will be based on the primary outcome. </plain></SENT>
<SENT sid="88" pm="."><plain>According to our pilot trial and review of the literature [15, 18–20], the proportion of change in 72-hour IEF from baseline for EA and PFMT plus solifenacin, is 57 and 60% respectively. </plain></SENT>
<SENT sid="89" pm="."><plain>To assess non-inferiority between the treatment and control groups, a sample size of 242 for each group will be sufficient, with a one-sided 5% level of significance, a power of 80% and allowing for a 15% dropout. </plain></SENT>
<SENT sid="90" pm="."><plain>This will exceed the non-inferiority margin of 15% [21]. </plain></SENT>
<SENT sid="91" pm="."><plain>Thus, in this trial, we will aim to recruit 250 participants in each group. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>Data from the 10 centers will be pooled, and the Clinical Evaluation Center of China Academy of Chinese Medical Sciences in Beijing will conduct the statistical analysis, using the SAS 9.1.3 (SAS Institute, Cary, NC, US) and SPSS Ver.13.0 (SPSS Inc., Chicago, IL, USA) software. </plain></SENT>
<SENT sid="93" pm="."><plain>All statistical analyses will be two-sided tests except for the primary outcome. </plain></SENT>
<SENT sid="94" pm="."><plain>The level of significance will be established at 0.05. </plain></SENT>
<SENT sid="95" pm="."><plain>Continuous data will be represented by the mean, standard deviation, median, minimum value, and maximum value; categorical data will be represented by percentages. </plain></SENT>
<SENT sid="96" pm="."><plain>For comparison with the baseline, a t-test or nonparametric test will be used for continuous data, and nonparametric tests for categorical data. </plain></SENT>
<SENT sid="97" pm="."><plain>For comparison of two independent samples a t-test or nonparametric test will be used for continuous data, and a chi-square test or the Fisher exact test will be used for categorical data. </plain></SENT>
<SENT sid="98" pm="."><plain>The primary outcome is the proportion of change from baseline in 72-h IEF. </plain></SENT>
<SENT sid="99" pm="."><plain>Analysis of covariance (for normal distributed data) or nonparametric tests (for abnormal distributed data) will be used. </plain></SENT>
<SENT sid="100" pm="."><plain>To detect the center effect, a covariance model will be used. </plain></SENT>
<SENT sid="101" pm="."><plain>Further analysis will be done if there is a center effect. </plain></SENT>
<SENT sid="102" pm="."><plain>Analysis methods for secondary outcomes are presented in Table 1. </plain></SENT>
<SENT sid="103" pm="."><plain>For safety analysis, incidence of adverse events will be compared between the two groups using the chi-square test or the Fisher exact test. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec13" sec-type="discussion"><title><text><SENT sid="104" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>In this non-inferiority, randomized controlled trial, we intend to compare the efficacy of EA versus PFMT plus solifenacin. </plain></SENT>
<SENT sid="106" pm="."><plain>Although PFMT is effective for the treatment of MUI, long-term adherence is necessary [6, 22]. </plain></SENT>
<SENT sid="107" pm="."><plain>Additionally, compliance with muscarinic antagonists is poor; owing to its side effects (such as dry mouth, constipation and blurred vision) [23]. </plain></SENT>
<SENT sid="108" pm="."><plain>Acupuncture is a non-toxic, economical intervention with minimal adverse effects [24], which has been shown to remain effective even for a few months after the therapy [25]. </plain></SENT>
<SENT sid="109" pm="."><plain>If the efficacy of EA is non-inferior to PFMT plus solifenacin, it may be a reasonable option in patients with MUI, requiring a conservative approach. </plain></SENT>
<SENT sid="110" pm="."><plain>One of the limitations in this trial design, is the non-blinding of the participants and acupuncturists. </plain></SENT>
<SENT sid="111" pm="."><plain>Due to the characteristics of acupuncture and the control (drug and PFMT), it is impossible to blind the participants and acupuncturists. </plain></SENT>
<SENT sid="112" pm="."><plain>However, we will rigorous methodology in other part of the study. </plain></SENT>
</text></p><sec id="Sec14"><title><text><SENT sid="113" pm="."><plain>Trial status </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>Twelve participants have been recruited. </plain></SENT>
</text></p></sec><sec id="Sec15"><title><text><SENT sid="115" pm="."><plain>Endnote </plain></SENT>
</text></title><p><text><SENT sid="116" pm="."><plain>aGuang’anmen Hospital; Dongzhimen Hospital (Beijing); West China Hospital (Chengdu); Yantai TCM Hospital (Yantai); Hengyang Hospital of Hunan University of Chinese Medicine (Hengyang); The First Hospital of Hunan University of Chinese Medicine (Changsha); Hubei Provincial Hospital of TCM (Wuhan); Jiangsu Province Hospital of TCM (Nanjing); Shanxi Province Hospital of TCM (Xi’an) and The Hiser Healthcare (Qingdao). </plain></SENT>
</text></p></sec></sec></SecTag></body><back><fn-group><fn><p><text><SENT sid="117" pm="."><plain>Competing interests </plain></SENT>
</text></p><p><text><SENT sid="118" pm="."><plain>The author(s) declare that they have no competing interests. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="119" pm="."><plain>Authors’ contributions </plain></SENT>
</text></p><p><text><SENT sid="120" pm="."><plain>ZL, BL and YC conceived the design of the trial. </plain></SENT>
<SENT sid="121" pm="."><plain>HX, JW and QM participated in the trial communication. </plain></SENT>
<SENT sid="122" pm="."><plain>YW drafted the manuscript and ZL revised it. </plain></SENT>
<SENT sid="123" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="124" pm="."><plain>This trial is supported financially by the 12th National Key Technology Support Program (No. 2012BAI24B01) and Project supported by the National Natural Science Foundation of China (Grant No. 81373732). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="125" pm="."><plain>1.GomelskyADmochowskiRRTreatment of mixed urinary incontinence in womenCurr Opin Obstet Gynecol2011235371375<?supplied-pmid 21836506?>21836506 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="126" pm="."><plain>2.HaylenBTde RidderDFreemanRMSwiftSEBerghmansBLeeJMongaAPetriERizkDESandPKSchaerGNAn international urogynecological association (IUGA)/International continence society (ics) joint report on the terminology for female pelvic floor dysfunctionInt Urogynecol J201021152610.1007/s00192-009-0976-9<?supplied-pmid 19937315?>19937315 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="127" pm="."><plain>3.HunskaarSBurgioKClarkALLapitanMCEpidemiology of Urinary (UI) and Faecal (FI) Incontinence and Pelvic Organ Prolapse (POP)2005ParisHealth Publication Ltd </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="128" pm="."><plain>4.ZhuLLangJLiuCXuTLiuXLiLWongFEpidemiological study of urge urinary incontinence and risk factors in ChinaInt Urogynecol J20102158959310.1007/s00192-009-1041-4<?supplied-pmid 20179907?>20179907 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="129" pm="."><plain>5.HunskaarSLoseGSykesDVossSThe prevalence of urinary incontinence in women in four European countriesBJU Int200493332433010.1111/j.1464-410X.2003.04609.x<?supplied-pmid 14764130?>14764130 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="130" pm="."><plain>6.PriceNDawoodRJacksonSRPelvic floor exercise for urinary incontinence: a systematic literature reviewMaturitas201067430931510.1016/j.maturitas.2010.08.004<?supplied-pmid 20828949?>20828949 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="131" pm="."><plain>7.Hay-SmithEJHerderscheeRDumoulinCHerbisonGPComparisons of approaches to pelvic floor muscle training for urinary incontinence in womenCochrane Database Syst Rev2011712CD00950822161451 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="132" pm="."><plain>8.DumoulinCJean HaySPelvic floor muscle training versus no treatment, or inactive control treatments for urinary incontinence in womenCochrane Database Syst Rev2011712CD00950822161451 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="133" pm="."><plain>9.KhanhTRobertMLShakerAMBehavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunctionAdv Urol2009345324 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="134" pm="."><plain>10.BasraRKelleherCA review of solifenacin in the treatment of urinary incontinenceTher Clin Risk Manag200841117128<?supplied-pmid 18728701?>18728701 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="135" pm="."><plain>11.GuayDRPClinical pharmacokinetics of drugs used to treat urge incontinenceClin Pharmacokinet2003421243128510.2165/00003088-200342140-00004<?supplied-pmid 14606931?>14606931 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="136" pm="."><plain>12.KimJHNamDParkMKLeeESKimSHRandomized control trial of hand acupuncture for female stress urinary incontinenceAcupunct Electrother Res20083317919210.3727/036012908803861122<?supplied-pmid 19301628?>19301628 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="137" pm="."><plain>13.MoQMaXLiuZCurative effect observation on the treatment of female stress urinary incontinence with electro-acupunctureBeijing J Tradit Chin Med201332434436 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="138" pm="."><plain>14.EngbergSCohenSSereikaSMThe efficacy of acupuncture in treating urge and mixed incontinence in women: a pilot studyJ Wound Ostomy Continence Nurs20093666167010.1097/WON.0b013e3181bd82dd<?supplied-pmid 19920749?>19920749 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="139" pm="."><plain>15.SandvikHSeimAVanvikAHunskaarSA severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing testsNeurourol Urodyn20001913714510.1002/(SICI)1520-6777(2000)19:2&lt;137::AID-NAU4&gt;3.0.CO;2-G<?supplied-pmid 10679830?>10679830 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="140" pm="."><plain>16.SandvikHEspunaMHunskaarSValidity of the incontinence severity indexL comparison with pad-weighing testsInt Urogynecol H Pelvic Floor Dysfunct200617552052410.1007/s00192-005-0060-z </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="141" pm="."><plain>17.National Collaborating Centre for Women’s and Chikdren’s HealthUrinary Incontinence: The Management of Urinary Incontinence in Women2006LondonNICE clinical guideline </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="142" pm="."><plain>18.KelleherCCardozoLKobashiKLucenteVSolifenacin: as effective in mixed urinary incontinence as in urge urinary incontinenceInt Urogynecol J Pelvic Floor Dysfunct20061738238810.1007/s00192-005-0023-4<?supplied-pmid 16283422?>16283422 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="143" pm="."><plain>19.EmmonsSLOttoLAcupuncture for overactive bladder: a randomized controlled trialObstet Gynecol200510613814310.1097/01.AOG.0000163258.57895.ec<?supplied-pmid 15994629?>15994629 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="144" pm="."><plain>20.SarDKhorshidLThe effects of pelvic floor muscle training on stress and mixed urinary incontinence and quality of lifeJ Wound Ostomy Continence Nurs20093642943510.1097/WON.0b013e3181aaf539<?supplied-pmid 19609165?>19609165 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="145" pm="."><plain>21.YalcinIRichardCBThe effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinenceAm J Obstet Gynecol2004191119419710.1016/j.ajog.2004.03.089<?supplied-pmid 15295364?>15295364 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="146" pm="."><plain>22.SiuLSChangAMYipSKCompliance with a pelvic muscle exercise program as a causal predictor of urinary stress incontinence amongst Chinese womenNeurourol Urodyn20032265966310.1002/nau.10110<?supplied-pmid 14595610?>14595610 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="147" pm="."><plain>23.SextonCCNotteSMMaroulisCDmochowskiRRCardozoLSubramanianDCoyneKSPersistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literatureInt J Clin Pract20116556758510.1111/j.1742-1241.2010.02626.x<?supplied-pmid 21489081?>21489081 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="148" pm="."><plain>24.WHO Library Cataloguing-in-Publication DataAcupuncture: Review and Analysis of Reports on Controlled Clinical Trials2002 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="149" pm="."><plain>25.CarlssonCPOSjolundBHAcupuncture for Chronic Low Back Pain: A Randomized Placebo-Controlled Study With Lont-Term Follow-UpClin J Pain20011729630510.1097/00002508-200112000-00003<?supplied-pmid 11783809?>11783809 </plain></SENT>
</text></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR26"><text><SENT sid="150" pm="."><plain>The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6882/14/301/prepub">http://www.biomedcentral.com/1472-6882/14/301/prepub</ext-link> </plain></SENT>
</text></ref></ref-list></ref-list></SecTag></back></article>
